Answers are grounded in this paper and cite their sources.
Background: IFD is a significant cause of illness and death among pediatric patients undergoing chemotherapy or HSCT. Application of AFP in children varies widely and is frequently off-label. This survey aims to describe real-world AFP practices across centers within AIEOP and provide an estimate of IFD incidence. Methods: In the second half of 2023, AIEOP centers participated in a web-based questionnaire collecting data on their AFP practices, antifungal agents, and IFD cases from 2021 to 2022. Results: Nineteen out of 44 AIEOP centers (43%) responded. AFP practices varied based on underlying disease and associated risk of IFD: it was used in 100% of centers treating AML, ALL-Rel, and allo-HSCT recipients, in 94.5% of centers for ALL-HR patients, and in 53% of centers with ALL-IR. Usage of AFP was limited (11%-35%) in low-risk patients (ALL-SR, HL, solid tumors). The most frequently used agents were liposomal amphotericin B and posaconazole for high-risk patients, and fluconazole for lower-risk patients. The estimated incidence of IFD was 4.7% (> 10% in ALL-Rel, NHL, allo-HSCT, SAA/AA). Conclusions: This survey shows variability in AFP drug choice. IFD rates remain elevated in high-risk groups. These results underline the need for updated, pediatric-specific national guidelines and antifungal stewardship to improve prophylaxis strategies. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
No takes yet. Share an insight, caveat, or question.
Colli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: